Topical Issues of Influenza Vaccine Prevention
Firuza Ch. Shakhtakhtinskaya,
Leyla S. Namazova-Baranova,
Marina V. Fedoseenko,
Tatiana A. Kaliuzhnaia https://doi.org/10.15690/vsp.v20i4.2291
Abstract
Influenza vaccination coverage has been expanding in recent years in Russian Federation. The topicality of influenza vaccination becomes more significant now at the beginning of seasonal increase in its prevalence, moreover, along with active immunization against coronavirus infection. Vaccination is crucial part in combined program of influenza prevention and control. Nowadays, the priority in influenza prevention is quadrivalent vaccines that can ensure the development of the most stable immunity. Russia has all the necessary resources to create and effectively implement modern influenza vaccines that meet international standards. Despite the remaining difficulties in combating influenza, preventive vaccination is by far the most effective method of protection that has proven its safety and efficacy.
Supporting agencies: Not specified
About the Authors
Firuza Ch. Shakhtakhtinskaya
Research Institute of Pediatrics and Children's Health in Central Clinical Hospital of the Russian Academy of Sciences; Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Other authors confirmed the absence of a reportable conflict of interests
Leyla S. Namazova-Baranova
Research Institute of Pediatrics and Children's Health in Central Clinical Hospital of the Russian Academy of Sciences; Pirogov Russian National Research Medical University; Belgorod State National Research University
Russian Federation
Disclosure of interest:
Russian Federation
Moscow; Belgorod
Disclosure of interest:
Leyla S. Namazova-Baranova — receiving research grants from pharmaceutical companies Pierre Fabre LLC, GenzymeEurope B.V., AstraZeneca Pharmaceuticals PLC, Gilead/PRA “Pharmaceutical Research Associates CIS”, Teva Branded Pharmaceutical Products R&D, Inc / “PPD Development LLC (Smolensk)” LLC, “Stallerzhen S.A.” / “Quintiles GMBH” (Austria)
Marina V. Fedoseenko
Research Institute of Pediatrics and Children's Health in Central Clinical Hospital of the Russian Academy of Sciences; Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
receiving grants from Pfizer, Sanofi Pasteur, MSD companies
Tatiana A. Kaliuzhnaia
Research Institute of Pediatrics and Children's Health in Central Clinical Hospital of the Russian Academy of Sciences; Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Other authors confirmed the absence of a reportable conflict of interests
References
1. WHO. Immunization in the context of COVID-19 pandemic Frequently Asked Questions (FAQ). 16 April 2020. World Health Organization. Available online: https://apps.who.int/iris/bitstream/handle/10665/331818/WHO-2019-nCoV-immunization_services-FAQ-2020.1-eng.pdf. Accessed on October 7, 2021.
2. Prioritetnaya vaktsinatsiya respiratornykh infektsii v period pandemii SARS-CoV-2 i posle ee zaversheniya: Manual for doctors / Kostinov MP, Chuchalin AG, eds. Moscow: Gruppa MDV; 2020. 32 p. (In Russ).
3. Briko NI, Nikiforov VV, Suranova TG, et al. Immunoprofilaktika i lechenie grippa: uspekhi i problemy. Lechaschi Vrach. 2019;(12):53-58. (In Russ).
4. The position of experts of the Union of Pediatricians of Russia regarding vaccination during a pandemic. April 2, 2020. (In Russ). Доступно по: https://www.pediatr-russia.ru/COVID-19/detail.php?ELEMENT_CODE=vaktsinatsiya-v-period-pandemii. Ссылка активна на 07.10.2021.
5. WHO. Global influenza strategy 2019-2030. World Health Organization. 2019. Available online: https://apps.who.int/iris/handle/10665/311184. Accessed on October 7, 2021.
6. Tatochenko VK. Guidelines on Prevention and Management of Influenza in Children in 2019/2020 yrs: American Academy of Pediatrics View. Voprosy sovremennoi pediatrii — Current Pediatrics. 2019;18(4):302-304. (In Russ). doi: 10.15690/vsp.v18i4.2048
7. Taghioff SM, Slavin BR, Holton T, Singh D. Examining the potential benefits of the influenza vaccine against SARS-CoV-2: A retrospective cohort analysis of 74,754 patients. PLoS ONE. 2021;16(8):e0255541. doi: 10.1371/journal.pone.0255541
8. Reina J. La vacunacion de la gripe en el tiempo del SARS-CoV-2. Med Clin (Barc). 2020;156(1):17-19. doi: 10.1016/j.medcli.2020.10.012
9. Bulgakova VA, Selimzyanova LR, Chemakina DS, Privalova TE. Vaccination against influenza in children — how it goes this season. Lechaschi Vrach. 2020;(5):54-58. (In Russ). doi: 10.26295/OS.2020.58.32.010
10. Order of the Ministry of Health of the Russian Federation dated March 21, 2014 N 125н “Ob utverzhdenii natsional'nogo kalen-darya profilakticheskikh privivok i kalendarya profilakticheskikh privivok po epidemicheskim pokazaniyam". (In Russ). Доступно по: https://www.rospotrebnadzor.ru/deyatelnost/epidemiolo-gical-surveillance/?ELEMENT_ID=5575. Ссылка активна на 07.10.2021.
11. Grohskopf LA, Alyanak E, Broder KR, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2019-20 Influenza Season. MMWR Recomm Rep. 2019; 68(RR-3):1-21. doi: 10.15585/mmwr.rr6803a1externalicon
12. Order of the Government of the Russian Federation dated September 18, 2020 N 2390-р “Ob utverzhdenii Strategii razvitiya immunoprofilaktiki infektsionnykh boleznei na period do 2035 goda". (In Russ). Доступно по: http://publication.pravo.gov.ru/Document/View/0001202009280074. Ссылка активна на 07.10.2021.
13. Popova AYu, Ezhlova EB, Melnikova AA, et al. The impact annual immunization against flu on morbidity of flu in the Russian Federation. Epidemiology and Vaccinal Prevention. 2016;15(1): 48-55. (In Russ).
14. Lioznov DA, Kharit SM, Erofeeva MK, et al. Assessment of reactoge-nicity and immunogenicity of the quadrivalent live attenuated influenza vaccine. Epidemiology and Vaccinal Prevention. 2018;17(3): 23-27. (In Russ). doi: 10.31631/2073-3046-2018-17-3-57-62
15. Osterhaus ADME. The relevance of tetravalent influenza vaccines. World experience. Epidemiology and Vaccinal Prevention. 2018;17(4):76-82. (In Russ).
16. Amiche A, Tanriover MD, Bellier L, et al. Cost Utility of Switching From Trivalent to Quadrivalent Influenza Vaccine in Turkey. Value Health Reg Issues. 2021;25:15-22. https://doi.org/10.1016/j.vhri.2020.11.006
Review
For citations:
Shakhtakhtinskaya F.Ch., Namazova-Baranova L.S., Fedoseenko M.V., Kaliuzhnaia T.A. Topical Issues of Influenza Vaccine Prevention. Current Pediatrics. 2021;20(4):333-337. (In Russ.) https://doi.org/10.15690/vsp.v20i4.2291
Views:
738
Email this article 
